# A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

> **NCT03375164** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **GENETIC:** delandistrogene moxeparvovec

## Key facts

- **NCT ID:** NCT03375164
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-04
- **Primary completion:** 2023-04-25
- **Final completion:** 2023-04-25
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03375164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03375164, "A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03375164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*